MX340402B - Inhibidores triciclicos de cinasas. - Google Patents

Inhibidores triciclicos de cinasas.

Info

Publication number
MX340402B
MX340402B MX2013009873A MX2013009873A MX340402B MX 340402 B MX340402 B MX 340402B MX 2013009873 A MX2013009873 A MX 2013009873A MX 2013009873 A MX2013009873 A MX 2013009873A MX 340402 B MX340402 B MX 340402B
Authority
MX
Mexico
Prior art keywords
kinases
tricyclic inhibitors
compounds
relates
present
Prior art date
Application number
MX2013009873A
Other languages
English (en)
Spanish (es)
Other versions
MX2013009873A (es
Inventor
Tong Yunsong
D Penning Thomas
Florjancic Alan
Miyashiro Julie
W Woods Keith
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2013009873A publication Critical patent/MX2013009873A/es
Publication of MX340402B publication Critical patent/MX340402B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2013009873A 2011-02-28 2012-02-27 Inhibidores triciclicos de cinasas. MX340402B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161447405P 2011-02-28 2011-02-28
PCT/US2012/026685 WO2012161812A1 (en) 2011-02-28 2012-02-27 Tricyclic inhibitors of kinases

Publications (2)

Publication Number Publication Date
MX2013009873A MX2013009873A (es) 2014-03-12
MX340402B true MX340402B (es) 2016-07-07

Family

ID=46000328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009873A MX340402B (es) 2011-02-28 2012-02-27 Inhibidores triciclicos de cinasas.

Country Status (11)

Country Link
US (1) US8710065B2 (cg-RX-API-DMAC7.html)
EP (1) EP2681221B1 (cg-RX-API-DMAC7.html)
JP (1) JP5886326B2 (cg-RX-API-DMAC7.html)
CN (1) CN103703005A (cg-RX-API-DMAC7.html)
AR (1) AR085502A1 (cg-RX-API-DMAC7.html)
CA (1) CA2827648A1 (cg-RX-API-DMAC7.html)
ES (1) ES2587514T3 (cg-RX-API-DMAC7.html)
MX (1) MX340402B (cg-RX-API-DMAC7.html)
TW (1) TWI532742B (cg-RX-API-DMAC7.html)
UY (1) UY33925A (cg-RX-API-DMAC7.html)
WO (1) WO2012161812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP3495367B1 (en) 2012-06-13 2020-09-30 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
JPWO2015029447A1 (ja) * 2013-08-30 2017-03-02 興和株式会社 光学活性カルビノール化合物の製造方法
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
AU2015245901B2 (en) * 2014-04-10 2017-05-25 Dalhousie University Treatment of Parkinson's disease through ArfGAP1 inhibition using substituted piperazine derivatives
CN107072970B (zh) * 2014-08-29 2021-05-25 得克萨斯州大学系统董事会 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
JP7240784B2 (ja) * 2016-11-16 2023-03-16 上海瑛派▲薬▼▲業▼有限公司 8,9-ジヒドロイミダゾール[1,2-a]ピリミド[5,4-e]ピリミジン-5(6H)-ケトン類化合物
ES2902050T3 (es) 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11345710B2 (en) 2017-07-10 2022-05-31 Impact Therapeutics (Shanghai), Inc Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
US11897867B2 (en) 2017-08-04 2024-02-13 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer
CN107821390A (zh) * 2017-10-13 2018-03-23 南京扬子鸿利源化学品有限责任公司 一种甲基磺草酮油悬浮剂及其制备方法
EP3712150B1 (en) 2017-11-01 2024-06-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as wee1 inhibitor and applications thereof
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
CN112771049B (zh) * 2018-09-27 2024-01-26 贝达药业股份有限公司 Fgfr4抑制剂及其应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Wee1阻害剤としてのピリミドピラゾロン類誘導体及びその使用
AR117929A1 (es) 2019-02-01 2021-09-01 Bayer Ag Compuestos de 1,2,4-triazin-3(2h)-ona
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
PT3964510T (pt) 2019-04-30 2024-07-29 Wuxi Biocity Biopharmaceutics Co Ltd Forma cristalina do composto inibidor de wee1 e sua utilização
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021073491A1 (zh) * 2019-10-16 2021-04-22 上海瑛派药业有限公司 二氢咪唑并嘧啶并嘧啶酮类化合物
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20230159540A1 (en) 2020-06-17 2023-05-25 Wigen Biomedicine Technology (shanghai) Co., Ltd. PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR
TWI823255B (zh) * 2021-02-19 2023-11-21 大陸商微境生物醫藥科技(上海)有限公司 作為Wee-1抑制劑的稠環化合物
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
AU2022265032A1 (en) * 2021-04-30 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
AU2022384370A1 (en) * 2021-11-09 2024-06-13 Hangzhou Glubio Pharmaceutical Co. Ltd. Wee1 protein kinase degradation agent and use thereof
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
WO2025188106A1 (ko) * 2024-03-08 2025-09-12 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000915A (es) 2003-07-25 2006-03-30 Novartis Ag Inhibidores de quinasa p-38.
US20050070554A1 (en) * 2003-08-27 2005-03-31 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
ES2566774T3 (es) * 2006-12-13 2016-04-15 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
ES2430053T3 (es) 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedimiento para producir derivados de bicicloanilina
CA2745970A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative

Also Published As

Publication number Publication date
EP2681221A1 (en) 2014-01-08
JP2014506929A (ja) 2014-03-20
US8710065B2 (en) 2014-04-29
ES2587514T3 (es) 2016-10-25
CN103703005A (zh) 2014-04-02
UY33925A (es) 2012-09-28
CA2827648A1 (en) 2012-11-29
TW201247675A (en) 2012-12-01
MX2013009873A (es) 2014-03-12
WO2012161812A1 (en) 2012-11-29
AR085502A1 (es) 2013-10-09
TWI532742B (zh) 2016-05-11
US20120220572A1 (en) 2012-08-30
JP5886326B2 (ja) 2016-03-16
EP2681221B1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
MX2013009873A (es) Inhibidores triciclicos de cinasas.
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
PH12017502141A1 (en) Compounds and their methods of use
MX2012013197A (es) Inhibidores de indazol de cinasa.
NZ630925A (en) Pyrazolopyrimidine compounds as kinase inhibitors
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
TN2012000559A1 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
UA115983C2 (uk) Інгібітори днк-пк
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
NZ708870A (en) Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
MX2013010898A (es) Novedoso derivados de la pirimidina.
PH12013502516A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX363551B (es) Compuestos derivados de pirazina como inhibidores de cinasa.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
TR201902034T4 (tr) Kanser hastalıklarının tedavisi için mdm2 inhibitörleri olarak piperidinon türevleri.

Legal Events

Date Code Title Description
FG Grant or registration